Zalicus to Merge with Epirus Biopharmaceuticals and PNC Financial Services Group Launches PINACLE Mobile App
Zalicus Inc. (NASDAQ: ZLCS) announced it would merge with Epirus Biopharmaceuticals in an all-stock transaction. After it closes Zalicus will be known as Epirus and will operate under the latter company's management team led by Amit Munshi as president and CEO. Current Zalicus stockholders will own approximately 19% of the company. The merger is going to create a publicly-traded company listed on the NASDAQ. "Under the new company structure, we will continue to aggressively advance our pipeline of biosimilars, and address diverse global biosimilar markets through local partnerships," Munshi